Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. HOWL
stocks logo

HOWL

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.357
-22.46%
--
--
-0.360
-10%
--
--
-0.360
-10%
Estimates Revision
The market is revising No Change the revenue expectations for Werewolf Therapeutics, Inc. (HOWL) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -26.20%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-26.20%
In Past 3 Month
Wall Street analysts forecast HOWL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HOWL is 9.00 USD with a low forecast of 7.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast HOWL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HOWL is 9.00 USD with a low forecast of 7.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.996
sliders
Low
7.00
Averages
9.00
High
10.00
Current: 0.996
sliders
Low
7.00
Averages
9.00
High
10.00
BofA
Jason Zemansky
Buy
downgrade
$8 -> $7
2025-11-18
Reason
BofA
Jason Zemansky
Price Target
$8 -> $7
2025-11-18
downgrade
Buy
Reason
BofA analyst Jason Zemansky lowered the firm's price target on Werewolf Therapeutics to $7 from $8 and keeps a Buy rating on the shares, citing an updated cash position following the company's Q3 update.
BofA
Jason Zemansky
Buy
downgrade
$9 -> $8
2025-08-25
Reason
BofA
Jason Zemansky
Price Target
$9 -> $8
2025-08-25
downgrade
Buy
Reason
BofA analyst Jason Zemansky lowered the firm's price target on Werewolf Therapeutics to $8 from $9 and keeps a Buy rating on the shares, citing the current cash position for the firm's revised target after a Q2 report that "didn't have many major updates." The firm still sees reasons to like the the second half setup with opportunities for a potential re-rating, the analyst tells investors.
Citizens JMP
Outperform
downgrade
$4 -> $3
2025-08-21
Reason
Citizens JMP
Price Target
$4 -> $3
2025-08-21
downgrade
Outperform
Reason
Citizens JMP lowered the firm's price target on Werewolf Therapeutics (HOWL) to $3 from $4 and keeps an Outperform rating on the shares. With important data updates coming in Q4, a partnership with Jazz Pharma (JAZZ), and a cash position of $77.6M, Werewolf represents an interesting investment opportunity, the analyst tells investors in a research note.
BofA
Buy
downgrade
$10 -> $9
2025-05-27
Reason
BofA
Price Target
$10 -> $9
2025-05-27
downgrade
Buy
Reason
Wedbush
Outperform -> NULL
downgrade
$8 -> $6
2025-05-09
Reason
Wedbush
Price Target
$8 -> $6
2025-05-09
downgrade
Outperform -> NULL
Reason
Wedbush lowered the firm's price target on Werewolf Therapeutics to $6 from $8 to adjust future financing expectations following the recent price decline, while keeping an Outperform rating on the shares following quarterly results and updates regarding PREDATOR-masked products. WTX-124 remains on track to report initial clinical data in the second half of 2025.
HC Wainwright & Co.
Andres Maldonado
Strong Buy
Reiterates
$15
2025-03-12
Reason
HC Wainwright & Co.
Andres Maldonado
Price Target
$15
2025-03-12
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Werewolf Therapeutics Inc (HOWL.O) is -0.69, compared to its 5-year average forward P/E of -3.05. For a more detailed relative valuation and DCF analysis to assess Werewolf Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.05
Current PE
-0.69
Overvalued PE
0.00
Undervalued PE
-6.10

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.91
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.52
Undervalued EV/EBITDA
-3.33

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
21.65
Current PS
0.00
Overvalued PS
47.56
Undervalued PS
-4.25
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 755.5% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

HOWL News & Events

Events Timeline

(ET)
2025-11-07
09:14:27
Werewolf Therapeutics unveils preclinical findings on the PREDATOR Platform
select
2025-11-04 (ET)
2025-11-04
07:10:27
Werewolf Therapeutics announces Q3 earnings per share of 36 cents, below consensus estimate of 38 cents.
select
2025-10-08 (ET)
2025-10-08
08:01:45
Werewolf Therapeutics Granted Fast Track Designation by U.S. FDA for WTX-124
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
12-03NASDAQ.COM
Biotech Stocks Rise After Hours: Clene Jumps Ahead of ALS Update; Werewolf, Biomea, and Dyne Also Gain

  • Clene Inc. Gains: Clene Inc. shares rose 8.53% in after-hours trading after announcing an upcoming investor call regarding its CNM-Au8 program for ALS, despite a regular session decline.

  • Werewolf Therapeutics Update: Werewolf Therapeutics saw a 6.12% increase after hours, likely influenced by investor reactions to its recent presentation at a cancer immunotherapy conference, despite no new news.

  • Biomea Fusion Presentation: Biomea Fusion's stock climbed 7.31% after hours following its announcement of an upcoming presentation on icovamenib data at a major diabetes and cardiovascular disease congress.

  • General Market Trends: Other biotech companies like Denali Therapeutics, TScan Therapeutics, and Nyxoah also experienced after-hours gains, reflecting ongoing investor interest and positioning ahead of regulatory milestones and presentations.

[object Object]
Preview
2.0
11-28NASDAQ.COM
Biotech Stocks MODD, LAB, HOWL, COGT, LGVN, and ABCL Surge in After-Hours Trading - Nov 26

  • Biotech Stocks Surge: Several biotech and life sciences companies experienced significant gains in after-hours trading on November 26, indicating strong investor interest despite a lack of major news.

  • Modular Medical's Approval: Modular Medical, Inc. saw an 11.51% increase in share price after receiving Institutional Review Board approval for its Pivot insulin delivery system study, which aims to gather critical data on device usability.

  • Standard BioTools Collaboration: Standard BioTools Inc. advanced 4.90% following a strategic partnership announcement with Molecular Instruments to enhance protein imaging capabilities through next-generation Imaging Mass Cytometry workflows.

  • Ongoing Investor Optimism: Companies like Werewolf Therapeutics, Cogent Biosciences, and Longeveron also reported gains, reflecting continued investor confidence in their research and development efforts, despite no new corporate updates.

[object Object]
Preview
9.0
10-08NASDAQ.COM
Werewolf Therapeutics Announces FDA Fast Track Designation for WTX-124 in Advanced Melanoma Treatment

  • Fast Track Designation: Werewolf Therapeutics has received Fast Track Designation from the FDA for WTX-124, aimed at treating patients with advanced cutaneous melanoma after standard immunotherapy, based on promising clinical data.

  • WTX-124 Therapy: WTX-124 is a conditionally activated IL-2 therapy designed to enhance anti-tumor immune responses while minimizing systemic side effects, currently being evaluated in a Phase 1/1b study alongside pembrolizumab for various advanced solid tumors.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Werewolf Therapeutics Inc (HOWL) stock price today?

The current price of HOWL is 0.9963 USD — it has increased 8.5 % in the last trading day.

arrow icon

What is Werewolf Therapeutics Inc (HOWL)'s business?

Werewolf Therapeutics, Inc. is a biopharmaceutical company engaged in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging its PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s advanced clinical-stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and IL-12 INDUKINE molecules for the treatment of solid tumors. It is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor. It is advancing WTX-712, WTX-518, and WTX-921 through preclinical development.

arrow icon

What is the price predicton of HOWL Stock?

Wall Street analysts forecast HOWL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HOWL is 9.00 USD with a low forecast of 7.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Werewolf Therapeutics Inc (HOWL)'s revenue for the last quarter?

Werewolf Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Werewolf Therapeutics Inc (HOWL)'s earnings per share (EPS) for the last quarter?

Werewolf Therapeutics Inc. EPS for the last quarter amounts to -0.36 USD, decreased -5.26 % YoY.

arrow icon

What changes have occurred in the market's expectations for Werewolf Therapeutics Inc (HOWL)'s fundamentals?

The market is revising No Change the revenue expectations for Werewolf Therapeutics, Inc. (HOWL) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -26.20%.
arrow icon

How many employees does Werewolf Therapeutics Inc (HOWL). have?

Werewolf Therapeutics Inc (HOWL) has 46 emplpoyees as of December 05 2025.

arrow icon

What is Werewolf Therapeutics Inc (HOWL) market cap?

Today HOWL has the market capitalization of 48.29M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free